| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
7,502 |
7,302 |
$455K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
4,538 |
4,372 |
$194K |
| 99395 |
Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years |
584 |
582 |
$42K |
| 99215 |
Prolong outpt/office vis |
402 |
392 |
$41K |
| 90791 |
Psychiatric diagnostic evaluation |
120 |
120 |
$13K |
| 59426 |
|
41 |
34 |
$10K |
| 99396 |
Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years |
103 |
103 |
$7K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
244 |
242 |
$6K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
395 |
390 |
$6K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
51 |
51 |
$5K |
| 72148 |
Magnetic resonance imaging, lumbar spine; without contrast material |
13 |
13 |
$4K |
| 72110 |
|
78 |
78 |
$3K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
89 |
39 |
$2K |
| G0444 |
Annual depression screening, 5 to 15 minutes |
510 |
509 |
$2K |
| 96139 |
|
22 |
12 |
$2K |
| 90674 |
|
52 |
52 |
$2K |
| 96132 |
|
12 |
12 |
$1K |
| 99442 |
|
18 |
16 |
$508.02 |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
54 |
54 |
$429.75 |
| 71046 |
Radiologic examination, chest; 2 views |
13 |
13 |
$395.46 |
| 96136 |
|
14 |
13 |
$387.05 |
| 72050 |
|
12 |
12 |
$385.84 |
| 96138 |
|
12 |
12 |
$257.40 |
| G0482 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed |
12 |
12 |
$249.04 |
| 80305 |
|
36 |
36 |
$187.40 |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
12 |
12 |
$158.51 |
| J1040 |
Injection, methylprednisolone acetate, 80 mg |
15 |
13 |
$106.03 |
| 3079F |
|
373 |
360 |
$60.00 |
| S0020 |
Injection, bupivicaine hydrochloride, 30 ml |
84 |
70 |
$42.77 |
| J1030 |
Injection, methylprednisolone acetate, 40 mg |
14 |
14 |
$41.58 |
| 36415 |
Collection of venous blood by venipuncture |
26 |
26 |
$32.25 |
| 3074F |
|
491 |
472 |
$20.00 |
| J0665 |
Injection, bupivicaine, not otherwise specified, 0.5 mg |
13 |
13 |
$0.13 |
| 3077F |
|
81 |
79 |
$0.00 |
| G8417 |
Bmi is documented above normal parameters and a follow-up plan is documented |
634 |
600 |
$0.00 |
| 99080 |
|
263 |
255 |
$0.00 |
| 3078F |
|
105 |
103 |
$0.00 |
| G8420 |
Bmi is documented within normal parameters and no follow-up plan is required |
371 |
345 |
$0.00 |
| 3080F |
|
35 |
34 |
$0.00 |
| J2001 |
Injection, lidocaine hcl for intravenous infusion, 10 mg |
29 |
26 |
$0.00 |
| G9903 |
Patient screened for tobacco use and identified as a tobacco non-user |
14 |
14 |
$0.00 |